In the latest trading session, 0.42 million Olema Pharmaceuticals Inc (NASDAQ:OLMA) shares changed hands as the company’s beta touched 2.08. With the company’s most recent per share price at $5.04 changing hands around $0.2 or 4.13% at last look, the market valuation stands at $374.19M. OLMA’s current price is a discount, trading about -232.74% off its 52-week high of $16.77. The share price had its 52-week low at $4.60, which suggests the last value was 8.73% up since then. When we look at Olema Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.47 million shares, with the 3-month average coming to 843.22K.
Analysts gave the Olema Pharmaceuticals Inc (OLMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended OLMA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Olema Pharmaceuticals Inc’s EPS for the current quarter is expected to be 0.17.
Olema Pharmaceuticals Inc (NASDAQ:OLMA) trade information
Instantly OLMA is in green as seen in intraday trades today. With action -8.36%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -13.55%, with the 5-day performance at -8.36% in the red. However, in the 30-day time frame, Olema Pharmaceuticals Inc (NASDAQ:OLMA) is -40.07% down. Looking at the short shares, we see there were 10.4 million shares sold at short interest cover period of 8.29 days.
The consensus price target for the stock as assigned by Wall Street analysts is 27, meaning bulls need an upside of 81.33% from its recent market value. According to analyst projections, OLMA’s forecast low is 27 with 27 as the target high. To hit the forecast high, the stock’s price needs a -435.71% plunge from its current level, while the stock would need to soar -435.71% for it to hit the projected low.
Olema Pharmaceuticals Inc (OLMA) estimates and forecasts
Data shows that the Olema Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -61.64% over the past 6 months, a -8.88% in annual growth rate that is considerably lower than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -105.28%. The 2025 estimates are for Olema Pharmaceuticals Inc earnings to decrease by -7.49%.
OLMA Dividends
Olema Pharmaceuticals Inc is expected to release its next quarterly earnings report in February.
Olema Pharmaceuticals Inc (NASDAQ:OLMA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.83% of Olema Pharmaceuticals Inc shares while 106.62% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.86%. There are 106.62% institutions holding the Olema Pharmaceuticals Inc stock share, with BVF INC/IL the top institutional holder. As of 2024-06-30, the company held 16.2322% of the shares, roughly 9.14 million OLMA shares worth $98.85 million.
PARADIGM BIOCAPITAL ADVISORS LP holds the second largest percentage of outstanding shares, with 14.0428% or 7.9 million shares worth $85.52 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.49 shares estimated at $7.53 million under it, the former controlled 2.00% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.37% of the shares, roughly 1.02 shares worth around $5.16 million.
